Rigel Pharmaceuticals (RIGL) Depreciation & Amortization (CF) (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Depreciation & Amortization (CF) of $597000.0 for Q1 2026, down 1.16% year-over-year from $604000.0 in Q1 2025, and down 0.67% quarter-over-quarter from $601000.0 in Q4 2025.
Powered by 
Analysis
Rigel Pharmaceuticals (RIGL) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $597000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 1.16% year-over-year to $597000.0; the TTM figure through Mar 2026 stood at $2.4 million (down 0.99% YoY), while the FY2025 annual figure was $2.4 million, up 8.39% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $597000.0, down from $601000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $613000.0 in Q2 2024, with the low at $237000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $400000.0 (2024), against an average of $439764.7.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) retreated 29.7% in 2022, then jumped 109.25% in 2024.
- Rigel Pharmaceuticals' Depreciation & Amortization (CF) stood at $284000.0 in 2022, then increased by 3.17% to $293000.0 in 2023, then surged by 106.14% to $604000.0 in 2024, then slipped by 0.5% to $601000.0 in 2025, then retreated by 0.67% to $597000.0 in 2026.
- Business Quant data shows RIGL's Depreciation & Amortization (CF) at $597000.0 in Q1 2026, $601000.0 in Q4 2025, and $603000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Rigel Pharmaceuticals | 901.09 Mn | 805.76 Mn | 70.18 Mn | 848,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 848,000.00 |
| Mar 31, 2026 | 597,000.00 |
| Dec 31, 2025 | 601,000.00 |
| Sep 30, 2025 | 603,000.00 |
| Jun 30, 2025 | 607,000.00 |
| Mar 31, 2025 | 604,000.00 |
| Dec 31, 2024 | 604,000.00 |
| Sep 30, 2024 | 611,000.00 |
| Jun 30, 2024 | 613,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | 293,000.00 |
| Sep 30, 2023 | 292,000.00 |
| Jun 30, 2023 | 296,000.00 |
| Mar 31, 2023 | 357,000.00 |
| Dec 31, 2022 | 284,000.00 |
| Sep 30, 2022 | 240,000.00 |
| Jun 30, 2022 | 237,000.00 |
| Mar 31, 2022 | 237,000.00 |
| Dec 31, 2021 | 404,000.00 |
| Sep 30, 2021 | 261,000.00 |